Skip to main content
SpringerLink
Log in

Wirkungen und Interaktionen der Biologika

Biologika sind, unter fachärztlicher Kontrolle angewendet, gut verträgliche und relativ sichere Medikamente

  • Biologika
  • Published:
rheuma plus Aims and scope

Durch die Einführung der Biologika und auch durch verbesserte konventionelle Therapieschemata ist die Wahrscheinlichkeit, eine klinische Remission oder zumindest eine niedrige Krankheitsaktivität bei Patientinnen und Patienten mit chronisch entzündlichen rheumatischen Erkrankungen zu erreichen, deutlich gestiegen. Sie ist aber, wie aus allen Untersuchungen – seien es klinische Studien oder Register – hervorgeht, noch lange nicht für alle Patienten gesichert. Weitere Untersuchungen, die zu einer Erhöhung der Wahrscheinlichkeit des individuellen Ansprechens auf einzelne Medikamente oder zumindest zu einer Verkürzung der Zeit bis zur Entscheidung über einen etwaigen Therapieerfolg führen, erscheinen genauso nötig wie neue Substanzen mit anderen Wirkprinzipien.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

  2. Leeb/ Biologika

  3. www.rheuma2000.at

  4. Bernatsky S, Habel Y, Rahme E, J Rheumatol 2010 Apr 1

  5. Simon TA, Askling J and Lacaille D (2010). Infections requiring hospitalization in abatacept clinical developement program: an epidemiological assessment. Arthritis Res Ther 12(2): R67

    PubMed  Google Scholar 

  6. Van Vollenhoven RF et al.: Experience with Mycobacterium Tuberculosis Infection reportet in the Tozilizumab Worldwide RA Safety Database. EULAR, Kopenhagen 2009. Abstract.#SAT0081 Ann Rheum Dis 2009; 68(Suppl3):567

  7. Graninger W et al: Konsensus Statement: B-Zelldepletierende Therapie der rheumatoiden Arthritis, Universum Innere Medizin 2007, Sonder-druck (08):1-4

  8. Gomez-ReinoJJ Carmona L and Angel Descalzo M (2007). Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57(5): 756–761

    Article  Google Scholar 

  9. Strangfeld A. et al: Risk of Zoster in Patients with RA treated with Anti-TNF-Agents; JAMA 2009 febr.-Vol 301 Nr.7

  10. MainiR, St Clair EW, Breedveld F et al: Infliximab (chimeric anti TNF) versus placebo in RA patients receiving concomitant MTX: a randomised phase III trial. ATTRACT Study Group. Lancet 1999 Dec4; 354(9194): 1932-9.

    Google Scholar 

  11. van de Putte LB, Atkins C, Mailaise M et al.: Efficacy and safety of adalimumab as monotherapy in pathients with RA for whom previous DMARDs treatment has failed. Ann Rheum Dis. 2004 May; 63(5): 508-16

    Google Scholar 

  12. Strand V, Mease P, Burmester GR et al.: Rapid and sustained improvements in HAQ-Score, fatigue, and other patient-reported outcomes in RA patients treated with certolizumab pegol plus MTX over one year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther. 2009;11(6): R170, Epub 2009 Nov 12

  13. Kay J, Matteson EL, Dasgupta B et al. Golimumab in patients with active RA despite treatment with MTX: a randomized, double-blind, placebo- controlled, dose-ranging study. Arthritis Rheum. 2008 Apr.;58(4): 964-75 Erratum in: Arthritis Rheum.2010 Nov; 62(11): 3518

  14. Moreland LW, Schiff MH, Baumgartner SW et al.: Etanercept therapy in RA. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6): 478-86

  15. Maini RN, Taylor PC, Szechinski J et al: double blind randomized controlled clinial trial of the IL6 receptor antagonist, tocilizumab, in european patients with RA who had an incomplete res- ponse to MTX. Arthritis Rheum.2006 sept;54(9): 2817-29. Erratum in; Arthritis Rheum. 2008 Mar; 58(3): 887

  16. Kremer JM, Dougados M, Emery P et al.: Treatment of RA withe the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebocontrolled trial. Arthritis Rheum. 2005 Aug;52(8): 2263-71. Erratum in Arthritis Rheum. 2005 Oct;52(10): 3321

  17. Emery P, Deodhar A, Rigby WF et al.: Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in pathients who ar biological naive with active RA and an inadequate response to MTX (Study evaluating Rituximab‘s Efficacy in MTX inadequate responders (SERENE). Ann Rheum Dis 2010 Sep; 69(9); 1629-35 Epub 1010 May 20

  18. Cohen sB, Moreland LW, Cush JJ et al.: A multicentre, double blind, randomised, placebo controlled trial of anakinra, a recombinant IL1 receptor antagonist, in patients with RA treated with background MTX. Ann Rheum Dis. 2004 Sept; 63(9): 1062-8, Eupub 2004 Apr 13

  19. Felson DT, Anderson JJ and Boers M (1993). The ACR preliminary core set of RA Disease Activity Measures of Clinical Trials. Arthritis Rheum 36(6): 729–740

    Article  PubMed  CAS  Google Scholar 

  20. Nam JL Winthrop KL, van Vollenhoven RF et al.: Current evidence for the management of RA with DMARDs: a systematic literature review informing the EULAR recommendations of management of RA. Ann Rheum Dis. 2010 Jun;69(6): 976-86. Eupub 2020 May 6

  21. Felson DT, Anderson JJ and Boers M (1995). ACR preliminary definition of improvement in RA. Arthritis Rheum 38: 727–35

    Article  PubMed  CAS  Google Scholar 

  22. Klareskog L, van der Heijde D and de Jager JP (2004). Therapeutic effect of the combination of etanercept and MTX compared with each treatment alone in patients with RA: double-blind randomised controlled trial. Lancet 363: 675–81

    Article  PubMed  CAS  Google Scholar 

  23. De Stefano R, Frati E, Nargi F et al.: Comparison of combination therapies in the treatment of RA: leflunomide-Anti-TNF-alpha versus MTX-anti- TNF-alpha. Clin.Rheumatol.2010 May;29(5): 517- 24. Epub 2010 Jan 16

  24. Furst DE, Schiff MH, Fleischmann RM et al.: Adalimumab, a fully human and TNF monoclonal antibody, and concomitand standard antirheumatic therapy for the treatment of RA: results of STAR (Safety Trial of Adalimumab in RA). J Rheumatol. 2003 Dec;30(12): 2563-71

  25. Genovese MC, Cohen S, Moreland L et al.; Combination therapy with etanercept and anakinra in the treatment of patients with RA who have been treated unsuccessfully with MTX. Arthritis Rheum 2004; 50: 1412-9

    Google Scholar 

  26. Singh JA, Christensen R, Wells GA et al.: A netowrk meta-analysis of randomised controlled trials of biologics for RA: a Cochrane overview. CMAJ. 2009 Nov.24; 181(11): 787-96

  27. Herold M, Böser M and Schirmer M (2004). Biologika in der Rheumatologie. Journal für Mineralstoffwechsel 11(3): 35–37

    Google Scholar 

  28. Wolfe F, Michaud K. Biologic treatment of RA and the risk of malignancy: analysis from a large US observentional study. Arthritis Rheum 2007 Sep; 56(9): 2886-95

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. I. und II. medizinische Abteilung, NÖ Kompetenzzentrum für Rheumatologie LK Weinviertel Stockerau, Landstrasse 18, 2000, Stockerau, Austria

    Kathrin Stingl

Authors
  1. Kathrin Stingl
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stingl, K. Wirkungen und Interaktionen der Biologika. rheuma plus 10, 12–16 (2011). https://doi.org/10.1007/s12688-011-0022-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12688-011-0022-0

Search

Navigation